Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 23 December 2008, doi:10.1136/bmj.a2931
Cite this as: BMJ 2008;337:a2931
Hernando León, postgraduate in internal medicine and former postdoctoral clinical research fellow 1,2, Marcelo C Shibata, associate clinical professor1,2, Soori Sivakumaran, associate clinical professor of medicine1,2, Marlene Dorgan, head 3, Trish Chatterley, research librarian3, Ross T Tsuyuki, professor of medicine (cardiology) and director1,2
1 Epidemiology Coordinating and Research (EPICORE) Centre, Edmonton, AB, Canada, 2 Department of Medicine, Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, 220 College Plaza, Edmonton, AB, Canada T6G 2C8, 3 Institute of Health Economics and John W Scott Health Sciences Library, University of Alberta
Correspondence to: R T Tsuyuki ross.tsuyuki{at}ualberta.ca
Design Systematic review and meta-analysis.
Data sources Medline, Embase, the Cochrane Library, PubMed, CINAHL, IPA, Web of Science, Scopus, Pascal, Allied and Complementary Medicine, Academic OneFile, ProQuest Dissertations and Theses, Evidence-Based Complementary Medicine, and LILACS.
Studies reviewed Randomised controlled trials of fish oil as dietary supplements in humans.
Data extraction The primary outcomes of interest were the arrhythmic end points of appropriate implantable cardiac defibrillator intervention and sudden cardiac death. The secondary outcomes were all cause mortality and death from cardiac causes. Subgroup analyses included the effect of formulations of EPA and DHA on death from cardiac causes and effects of fish oil in patients with coronary artery disease or myocardial infarction.
Data synthesis 12 studies totalling 32 779 patients met the inclusion criteria. A neutral effect was reported in three studies (n=1148) for appropriate implantable cardiac defibrillator intervention (odds ratio 0.90, 95% confidence interval 0.55 to 1.46) and in six studies (n=31 111) for sudden cardiac death (0.81, 0.52 to 1.25). 11 studies (n=32 439 and n=32 519) provided data on the effects of fish oil on all cause mortality (0.92, 0.82 to 1.03) and a reduction in deaths from cardiac causes (0.80, 0.69 to 0.92). The dose-response relation for DHA and EPA on reduction in deaths from cardiac causes was not significant.
Conclusions Fish oil supplementation was associated with a significant reduction in deaths from cardiac causes but had no effect on arrhythmias or all cause mortality. Evidence to recommend an optimal formulation of EPA or DHA to reduce these outcomes is insufficient. Fish oils are a heterogeneous product, and the optimal formulations for DHA and EPA remain unclear.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses